-
EP1096937
European procedure
Extract from the Register of European Patents
EP About this file: EP1096937
| EP1096937 - SUSTAINED RELEASE RANOLAZINE FORMULATIONS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 17.10.2008 Database last updated on 12.10.2024 | Most recent event Tooltip | 17.10.2008 | No opposition filed within time limit | published on 19.11.2008 [2008/47] | 17.10.2008 | Change - no opposition filed | published on 19.11.2008 [2008/47] | 17.10.2008 | Change - inventor | published on 19.11.2008 [2008/47] | Applicant(s) | For all designated states CV THERAPEUTICS, INC. 3172 Porter Drive Palo Alto, CA 94304 / US | [2001/19] | Inventor(s) | 01 /
WOLFF, Andrew, A. 1140 Lawton Street San Francisco, CA 94122 / US | 02 /
LANGRIDGE, John Richard Schootsedjik 35 5491 TD Sint Oedenrode / NL | 03 /
BAKER, Fiona 1 Afton Grove Fife KY11 4LE Dunfermline / GB | [2008/47] |
| Former [2001/19] | 01 /
WOLFF, Andrew, A. 1140 Lawton Street San Francisco, CA 94122 / US | Representative(s) | Grund, Martin, et al Dr. Volker Vossius Patentanwaltskanzlei Geibelstrasse 6 81679 München / DE | [N/P] |
| Former [2001/19] | Grund, Martin, Dr., et al Dr. Volker Vossius, Patentanwaltskanzlei, Holbeinstrasse 5 81679 München / DE | Application number, filing date | 99948196.3 | 09.09.1999 | [2001/19] | WO1999US20968 | Priority number, date | US19980099804P | 10.09.1998 Original published format: US 99804 P | US19990321522 | 27.05.1999 Original published format: US 321522 | [2001/19] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO0013687 | Date: | 16.03.2000 | Language: | EN | [2000/11] | Type: | A2 Application without search report | No.: | EP1096937 | Date: | 09.05.2001 | Language: | EN | The application published by WIPO in one of the EPO official languages on 16.03.2000 takes the place of the publication of the European patent application. | [2001/19] | Type: | B1 Patent specification | No.: | EP1096937 | Date: | 29.12.2004 | Language: | EN | [2004/53] | Type: | B9 Corrected patent specification | No.: | EP1096937 | Date: | 28.02.2007 | [2007/09] | Search report(s) | International search report - published on: | EP | 29.06.2000 | Classification | IPC: | A61K31/495, A61K9/20, A61K9/36, A61P9/00, A61P9/06, A61P9/10 | [2004/31] | CPC: |
A61K9/2846 (EP,US);
A61K9/20 (KR);
A61K31/495 (EP,US);
A61K31/496 (EP,US);
A61K9/2027 (EP,US);
A61K9/205 (EP,US);
A61K9/2054 (EP,US);
A61K9/2077 (EP,US);
A61K9/2866 (EP,US);
|
| Former IPC [2001/19] | A61K31/495, A61K9/20 | Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2001/19] | Extension states | AL | 09.03.2001 | LT | 09.03.2001 | LV | 09.03.2001 | MK | 09.03.2001 | RO | 09.03.2001 | SI | 09.03.2001 | Title | German: | RANOLAZINHALTIGE ARZNEIMITTEL MIT VERZÖGERTER WIRKSTOFFABGABE | [2001/19] | English: | SUSTAINED RELEASE RANOLAZINE FORMULATIONS | [2001/19] | French: | FORMULATIONS DE RANOLAZINE A LIBERATION LENTE | [2001/19] | Entry into regional phase | 09.03.2001 | National basic fee paid | 09.03.2001 | Designation fee(s) paid | 09.03.2001 | Examination fee paid | Examination procedure | 22.03.2000 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 09.03.2001 | Amendment by applicant (claims and/or description) | 09.03.2001 | Examination requested [2001/19] | 09.03.2001 | Request for accelerated examination filed | 18.06.2002 | Despatch of a communication from the examining division (Time limit: M04) | 18.06.2002 | Decision about request for accelerated examination - accepted: Yes | 18.10.2002 | Reply to a communication from the examining division | 23.04.2003 | Despatch of a communication from the examining division (Time limit: M04) | 25.06.2003 | Reply to a communication from the examining division | 07.06.2004 | Date of oral proceedings | 01.07.2004 | Minutes of oral proceedings despatched | 12.07.2004 | Communication of intention to grant the patent | 06.10.2004 | Fee for grant paid | 06.10.2004 | Fee for publishing/printing paid | Divisional application(s) | EP04030151.7 / EP1527779 | EP10011228.3 Application refused : 17.03.2011 | Opposition(s) | 30.09.2005 | No opposition filed within time limit [2005/51] | Fees paid | Renewal fee | 24.09.2001 | Renewal fee patent year 03 | 23.09.2002 | Renewal fee patent year 04 | 24.09.2003 | Renewal fee patent year 05 | 23.09.2004 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [AD]US4567264 (KLUGE ARTHUR F [US], et al) [AD] 1,2,6,8,13,20,24 * claim - * * examples 12,14 *; | [AD]EP0407780 (SYNTEX PHARMA LTD [GB]) [AD] 1,2,6,8,13,20,24 * claims 14,15 * * examples C,D *; | [AD]WO9426266 (SYNTEX INC [US]) [AD] 1,2,6,8,13,20,24 * claims 1,2,4-6,10-13,15 * * page 3, line 16 - line 19 * * page 4, line 37 - page 5, line 13 * * page 7, line 9 - line 11 *; | [A] - CHEMICAL ABSTRACTS, (19941205), vol. 121, no. 23, Database accession no. 271766, XP002133147 [A] 1,2,6,8,13,20,24 * abstract * | [ ] - M.R.GRALINSKI ET AL., "CARDIOPROTECTIVE EFFECTS OF RANOLAZINE (RS-43285) IN THE ISOLATED PERFUSED RABBIT HEART", CARDIOVASC. RES., (1994), vol. 28, no. 8, pages 1231 - 1237 | [A] - CHEMICAL ABSTRACTS, (19980706), vol. 129, no. 1, Database accession no. 24, XP002133148 [A] 1,2,6,8,13,20,24 * abstract * | [ ] - J.G.MCCORMACK ET AL., "RANOLAZINE:A NOVEL METABOLIC MODULATOR FOR THE TREATMENT OF ANGINA.", GEN. PHARMACOL., (1998), vol. 30, no. 5, pages 639 - 645 |